UPEXI INC
For the period ended Jun 30, 2024. Filed Dec 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 16, 2024
UPXI$0.66+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
UPEXI, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
| Year Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | ||
| Revenue | $26,000,652 | $36,441,695 |
| Cost of Revenue | 13,176,073 | 15,421,715 |
| Gross profit | 12,824,579 | 21,019,980 |
| Operating expenses | ||
| Sales and marketing | 5,989,727 | 6,067,392 |
| Distribution costs | 8,611,702 | 9,465,149 |
| General and administrative expenses | 6,771,937 | 6,875,575 |
| Share-based compensation | 1,169,843 | 3,664,538 |
| Amortization of acquired intangible assets | 2,410,431 | 2,568,502 |
| Depreciation | 1,268,355 | 913,246 |
| Impairment of long-lived asset - building | 336,434 | - |
| Loss on the sale / abandonment of assets in relocation | 569,195 | - |
| Impairment of intangible assets and goodwill | 7,869,425 | 3,746,301 |
| Lease impairment, Delray Beach facility | 289,969 | - |
| 35,287,018 | 33,300,703 | |
| Loss from operations | (22,462,439) | (12,280,723) |
| Other income (expense), net | ||
| Change in derivative liability | - | 1,770 |
| Other | (16,443) | 38,344 |
| Interest (expense) income, net | (3,124,723) | (4,716,274) |
| Other income (expense), net | (3,141,166) | (4,676,160) |
| Loss on operations before income tax | (25,603,605) | (16,956,883) |
| Income tax benefit | 332,101 | 3,049,293 |
| 332,101 | 3,049,293 | |
| Net income (loss) from continuing operations | (25,271,504) | (13,907,590) |
| Gain (loss) from the sale of: | ||
| Infusionz and select assets | - | (2,212,542) |
| Interactive Offers | 237,670 | - |
| VitaMedica | 1,948,538 | - |
| E-core | (1,737,326) | - |
| 448,882 | (2,212,542) | |
| Income (loss) on discontinued operations | ||
| Infuisionz | 71,976 | (338,418) |
| Interactive offers | (187,003) | (1,729,636) |
| VitaMedica | 213,636 | (382,449) |
| E-core | 1,065,575 | 1,080,379 |
| Income (loss) income from discontinued operations | 1,164,184 | (1,370,124) |
| Net loss attributable to non-controlling interest | - | 559,967 |
| Net income (loss) attributable to Upexi, Inc. | $(23,658,438) | $(16,930,289) |
| Basic income (loss) per share: | ||
| Income (loss) per share from continuing operations | $(24.60) | $(15.56) |
| (Loss) income per share from discontinued operations | $1.13 | $(1.53) |
| Total income (loss) per share attributable to Upexi shareholders | $(23.03) | $(18.94) |
| Diluted income (loss) per share: | ||
| Income (loss) per share from continuing operations | $(24.60) | $(15.56) |
| (Loss) income per share from discontinued operations | $1.13 | $(1.53) |
| Total income (loss) per share attributable to Upexi shareholders | $(23.03) | $(18.94) |
| Basic weighted average shares outstanding | 1,027,232 | 893,943 |
| Fully diluted weighted average shares outstanding | 1,027,232 | 893,943 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.